Amygdala Neurosciences Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $5.6M
Latest Deal Amount
  • Investors
  • 2

Amygdala Neurosciences General Information

Description

Operator of a biopharmaceutical firm intended to focus on the large and growing unmet need associated with substance use disorders. The company's firm uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated craving without changes to basal dopamine, enabling patients to quit and get rid of the addiction to drugs, alcohol, and smoking.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 5214F Diamond Heights Boulevard
  • Suite 151
  • San Francisco, CA 94131
  • United States
+1 (650) 000-0000

Amygdala Neurosciences Timeline

2017201820192020
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amygdala Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 02-Nov-2019 $5.6M 000.00 Completed Generating Revenue
5. Grant 21-Oct-2019 00.000 00.000 Completed Generating Revenue
4. Grant 19-Sep-2018 000.00 00.000 Completed Generating Revenue
3. Seed Round 19-May-2017 00.000 00.000 000.00 Completed Generating Revenue
2. Seed Round 10-Feb-2017 $2M $3.45M 000.00 Completed Generating Revenue
1. Seed Round 10-Apr-2015 $1.45M $1.45M 000 Completed Generating Revenue
To view Amygdala Neurosciences’s complete valuation and funding history, request access »

Amygdala Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-3 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Seed-2 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed-1 5,307,464 $0.000100 $0.02 $0.27 $0.27 1x $0.27 25.3%
To view Amygdala Neurosciences’s complete cap table history, request access »

Amygdala Neurosciences Executive Team (6)

Name Title Board Seat Contact Info
Peter Strumph Co-Founder, President, Chief Executive Officer and Board Member
Adrienne MacMillan Co-Founder & Chief Financial Officer
Brent Blackburn Ph.D Co-Founder & Chief Development Officer
Ivan Diamond Ph.D Co-Founder, Board Member & Chief Scientific Officer
Louis Lange MD Co-Founder & Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Amygdala Neurosciences Board Members (6)

Name Representing Role Since
Howard Jaffe Amygdala Neurosciences Board Member 000 0000
Ivan Diamond Ph.D Amygdala Neurosciences Co-Founder, Board Member & Chief Scientific Officer 000 0000
Louis Lange MD Amygdala Neurosciences Co-Founder & Chairman 000 0000
Mack Mitchell MD Self Chief Medical Officer & Board Member 000 0000
Peter Strumph Amygdala Neurosciences Co-Founder, President, Chief Executive Officer and Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Amygdala Neurosciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Amygdala Neurosciences’s complete investors history, request access »

Amygdala Neurosciences Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000 (0 16-Feb-2017 000000000 00000 00 Buildings and Property 00000 0000000
To view Amygdala Neurosciences’s complete investments history, request access »